KPV
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A tripeptide fragment of the hormone alpha-MSH, marketed for gut and skin inflammation and mucosal healing. Its anti-inflammatory mechanism (blocking the NF-kB pathway) is characterized in cell and animal models, and no human clinical trials or safety studies have been completed. The FDA has stated it lacks human exposure and safety data. Most supply is unregulated research-grade product of uncertain purity, and it is not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
KPV is a naturally occurring anti-inflammatory tripeptide (just three amino acids: lysine-proline-valine) derived from alpha-MSH, a hormone involved in skin pigmentation and immune regulation. Despite its tiny size, KPV retains most of the potent anti-inflammatory activity of the full parent hormone. Unlike alpha-MSH, KPV does not work through the melanocortin receptors but instead enters cells via a dedicated transporter (PepT1) and directly shuts down inflammatory signaling pathways inside the cell. It has generated particular interest for inflammatory bowel conditions.
How it works in the body
A tripeptide fragment from alpha-MSH (alpha-melanocyte-stimulating hormone). It enters cells and directly inhibits the NF-kB inflammatory pathway by preventing the p65 subunit from entering the nucleus. This broadly reduces inflammation in gut tissue, skin, and other organs without needing to bind a cell-surface receptor.
Research overview
KPV research is entirely preclinical as of 2026, with zero human clinical trials completed. The FDA has stated it has not identified any human exposure data on KPV. The evidence consists of cell studies and rodent colitis models. Key findings show that KPV suppresses two major inflammatory signaling pathways (NF-kB and MAPK) at very low concentrations. Notably, inflamed gut tissue naturally upregulates the PepT1 transporter that carries KPV into cells, making diseased tissue a preferential target ā a compelling feature for potential oral therapy. In animal models of inflammatory bowel disease, oral KPV significantly reduced colon inflammation, prevented weight loss, and lowered pro-inflammatory markers. In one study, it rescued all animals from death in a severe colitis model. Advanced nanoparticle delivery systems have been developed to improve oral absorption and targeted delivery to the colon. Despite promising animal data, the complete absence of human studies means safety and efficacy in people remain unknown.
Who researches KPV?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching GI and digestive health
Studied for gastrointestinal protection, gut lining repair, or digestive support.
Important considerations for
Those with Active infection requiring immune response
ModerateKPV's strong anti-inflammatory action via NF-kB suppression may impair immune defense during active infection.
Those with Organ transplant recipients
ModerateImmune-modulating properties may interact with immunosuppressive regimens unpredictably.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data for this MSH-derived peptide.
Safety & interactions
Do not use if
Active infection requiring immune response
ModerateKPV's strong anti-inflammatory action via NF-kB suppression may impair immune defense during active infection.
Organ transplant recipients
ModerateImmune-modulating properties may interact with immunosuppressive regimens unpredictably.
General cautions
Pregnancy
AbsoluteNo reproductive safety data for this MSH-derived peptide.
How to read the ratings
- Benefits
- = confidence in the evidence: High Ā· Medium Ā· Low Ā· Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High Ā· Moderate Ā· Low Ā· Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic Ā· Caution Ā· Neutral
Risk summary(6)
Rated by level of concern
Zero human clinical trials or safety studies completed
HighLiterature review (all primary KPV studies are preclinical); FDA 503A/PCAC KPV briefing document, released ahead of the July 23-24, 2026 PCAC meeting
FDA has explicitly stated it lacks human exposure/safety data on KPV
HighFDA 503A Bulk Drug Substances briefing document ahead of PCAC meeting, July 23-24, 2026 (Drug Topics; RAPS coverage; ECRI-ISMP compounded-peptide white paper, Apr 2026)
Theoretical immunosuppression risk
TheoreticalMechanism-based (Dalmasso 2008 PMID 18061177; tolerance data from contact-hypersensitivity models)
Contraindicated in pregnancy, breastfeeding, cancer history
LowAbsence of reproductive/oncology human data; anti-tumorigenic mouse data (Viennois et al., Cell Mol Gastroenterol Hepatol 2016, PMID 27458604)
Research-grade products may have purity/contamination issues
ModerateECRI-ISMP White Paper on Compounded Peptide Products, Apr 2026; FDA compounded-peptide quality concerns
Long-term effects unknown
ModerateLiterature review (no long-term human KPV data)
Interaction summary(6)
Rated by direction with this peptide
Systemic immunosuppressants (corticosteroids, calcineurin inhibitors)
CautionTheoreticalKPV's NF-kB suppression and tolerance-inducing activity could theoretically add to systemic immunosuppression; no human interaction data exist.
Mechanism-based (Dalmasso et al. 2008, PMID 18061177)
PepT1-substrate drugs (oral beta-lactam antibiotics, ACE inhibitors e.g. captopril, valacyclovir/valganciclovir)
CautionTheoreticalKPV is absorbed through the PepT1 transporter, so co-administration could compete for transport and alter absorption of either agent. (The named agents are all canonical PepT1 substrates.)
PepT1-mediated KPV uptake, PMID 18061177 / PMC2431115
TNF-alpha inhibitors / IBD biologics (e.g. infliximab, adalimumab)
SynergisticTheoreticalOverlapping cytokine/NF-kB suppression could be additive in inflammatory bowel disease, with a parallel theoretical caution for excess immunosuppression to monitor.
Mechanism-based (shared NF-kB/cytokine pathway; PMID 18061177)
Oral 5-aminosalicylates (mesalamine, sulfasalazine)
SynergisticTheoreticalBoth reduce intestinal NF-kB-driven inflammation, suggesting a theoretical additive gut anti-inflammatory effect rather than a harmful interaction.
Mechanism-based (colitis-model anti-inflammatory activity, PMID 18061177)
Live attenuated vaccines
CautionTheoreticalBy analogy to other immunomodulators, KPV's tolerogenic/anti-inflammatory effects could theoretically blunt vaccine response; not demonstrated for KPV.
Mechanism/class analogy (no KPV-specific data)
Active chemotherapy / cytotoxic cancer therapy
CautionTheoreticalEffects of KPV immunomodulation during active oncologic treatment are uncharacterized in humans; direction is uncertain, warranting caution despite anti-tumorigenic signals in a mouse colitis-associated cancer model.
Mechanism-based; anti-tumorigenic mouse data (Viennois et al., Cell Mol Gastroenterol Hepatol 2016, PMID 27458604)
Known risks(7)
Zero human clinical trials or safety studies completed
FDA has explicitly stated it lacks human exposure/safety data on KPV
Theoretical immunosuppression risk ā may impair immune response to infections
Contraindicated in pregnancy, breastfeeding, and individuals with cancer history
Unregulated products sold online may have purity/contamination issues
Long-term effects completely unknown ā no chronic exposure data in any species
Potential for additive immunosuppression if combined with immunosuppressive medications
Drug interactions(5)
Immunosuppressants (e.g., tacrolimus, cyclosporine, methotrexate)
Theoretical additive immunosuppression. KPV inhibits NF-kB which is also a target of many immunosuppressants. No clinical interaction data exists.
NSAIDs (e.g., ibuprofen, naproxen)
Both reduce inflammation through different mechanisms. Combined effects on gut mucosa are unstudied.
Biologic DMARDs (e.g., infliximab, adalimumab)
Anti-TNF biologics and KPV both suppress TNF-alpha. Combining may produce excessive immunosuppression. Not studied.
Corticosteroids
Both suppress NF-kB-mediated inflammation. Additive immunosuppression possible. No interaction data.
BPC-157
Both target gut healing through different mechanisms. BPC-157 promotes angiogenesis, KPV suppresses NF-kB. Used together in some clinical protocols.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 25
- Human Studies
- 0
100% of evidence is from cell culture and animal models. No human safety, pharmacokinetic, or efficacy data exists. FDA has stated it lacks human exposure data on KPV. Multiple rodent colitis models show consistent anti-inflammatory efficacy.
Researched for(7)
Rated by confidence in the evidence
Intestinal anti-inflammatory activity
MediumMouse colitis models show reduced colonic inflammation and tissue damage.
Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115
NF-kB pathway inhibition
MediumBlocks NF-kB and MAPK inflammatory signaling at nanomolar concentrations in cell studies.
Dalmasso et al., Gastroenterology 2008, PMID 18061177; Kannengiesser et al., Inflamm Bowel Dis 2008, PMID 18092346
Pro-inflammatory cytokine reduction
MediumLowers IL-1beta, IL-6, TNF-alpha, and IFN-gamma while sparing anti-inflammatory IL-10.
Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115
Targeted uptake via PepT1 transporter
MediumEnters cells via PepT1, which rises in inflamed IBD tissue, concentrating it where needed.
Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115
Antimicrobial properties
SpeculativeAlpha-MSH peptides including KPV show antimicrobial activity in early lab work.
Cutuli et al., J Leukoc Biol 2000;67(2):233-239, PMID 10670585
Skin inflammation reduction
LowPreliminary animal and cell studies suggest anti-inflammatory effects on skin.
Contact-hypersensitivity/tolerance mouse data (Brzoska & Luger melanocortin studies); KPV keratinocyte MAPK/NF-kB suppression (Lysine-Proline-Valine fine-dust keratinocyte study, 2025).
Mucosal healing acceleration
LowA single colitis study reported reduced mucosal damage alongside lower inflammation.
Dalmasso et al., Gastroenterology 2008, PMID 18061177 (reduced mucosal damage in DSS/TNBS colitis)
Benefits(7)
Intestinal anti-inflammatory activity
NF-kB pathway inhibition
Pro-inflammatory cytokine reduction
Targeted uptake via PepT1 transporter
Antimicrobial properties
Skin inflammation reduction
Mucosal healing acceleration
Key studies(5)
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Preclinical (in vitro + in vivo)5-10 mice per group8 days (DSS model), 48 hours (TNBS model)Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D
Gastroenterology
2008
KPV transported by PepT1 into intestinal epithelial and immune cells. Nanomolar KPV inhibits NF-kB and MAPK. Oral KPV reduced MPO ~50% in DSS colitis and ~30% in TNBS colitis. Mechanism independent of melanocortin receptors.
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Preclinical (in vivo)Multiple groups of miceVariable (DSS and transfer colitis models)Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T
Inflammatory Bowel Diseases
2008
KPV led to earlier recovery and significantly stronger weight regain in DSS colitis. Reduced inflammatory infiltrates and MPO. In MC1R-deficient mice, KPV rescued all animals from DSS colitis death.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Preclinical (in vitro + in vivo)Multiple groups of miceVariableXiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D
Molecular Therapy
2017
HA-coated KPV nanoparticles (~272nm) achieved targeted colonic delivery. Oral HA-KPV-NPs showed stronger capacity to prevent mucosa damage and downregulate TNF-alpha vs. uncoated nanoparticles. Nontoxic and biocompatible.
Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides
Preclinical (in vitro and in vivo)N/A (cell studies)Getting SJ, Schiƶth HB, Perretti M
Journal of Pharmacology and Experimental Therapeutics
2003
KPV anti-inflammatory effect is clearly different from core MSH peptides. KPV unlikely to act through melanocortin receptors, more likely acts through inhibition of IL-1beta functions.
Singh M, Mukhopadhyay K
BioMed Research International
2014
Comprehensive review of alpha-MSH and derivative peptides including KPV as anti-inflammatory and antimicrobial agents. KPV retains anti-inflammatory properties of full-length alpha-MSH.
What research suggests over time
Weeks 2-4
Preclinical onlyNo human dosing-trial data. Preclinical models show anti-inflammatory effects on gut tissue within days of oral or IP dosing.
Months 2-3
Preclinical (mouse colitis)Earlier recovery and stronger weight regain vs vehicle in DSS colitis mice; reduced inflammatory infiltrates (Inflamm Bowel Dis 2008).
Long-term
Preclinical only100% preclinical evidence base; no human safety, PK, or efficacy data. Placed on FDA Category 2 in 2023 (withdrawn in April 2026); in a draft interim policy posted October 28, 2026 and open for public comment until mid-November, HHS said it does not intend to act against limited oral and topical compounding under conditions.
Regulation & availability
Why researchers look at it
Inflamed gut tissue naturally upregulates the transporter (PepT1) that carries KPV into cells, creating a built-in targeting system where diseased tissue preferentially absorbs the peptide ā and animal colitis models showed it rescued all subjects from death. Despite these striking preclinical results, the FDA has stated it has identified no human exposure data on KPV.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Not FDA-approved. KPV was placed in 503A Category 2 in 2023; its nomination was subsequently withdrawn. It is not in current Category 1 or on the final 503A bulks list. FDA's 2026 review found no human exposure studies. FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026; FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it.
- WADA status
- Not individually named in the 2026 List. S0 prohibits pharmacological substances without current governmental approval anywhere for human therapeutic use, unless covered elsewhere in the List. Athletes should confirm KPV's compound-specific status with their anti-doping organization.
- Prescribability
- KPV is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing KPV; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
- Availability
- Not available as an FDA-approved medicine. KPV is absent from current 503A Category 1 and the final 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Injectable KPV is outside the policy. Unregulated products sold online carry quality and safety risks.
International status
EU
Not approved
US
KPV is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing KPV; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Australia
Not approved
Regulatory timeline(5)
- 2003Early mechanistic researchGetting et al. report that KPV has anti-inflammatory effects distinct from core MSH peptides and is unlikely to act through melanocortin receptors.
- 2008Key preclinical studies publishedDalmasso et al. (Gastroenterology) and Kannengiesser et al. (IBD) establish PepT1-mediated mechanism and efficacy in colitis models.
- 2017Nanoparticle delivery advanceXiao et al. develop HA-functionalized KPV nanoparticles for targeted oral delivery to inflamed colon.
- 2023-09FDA Category 2 restrictionKPV placed on Category 2 list, restricted from compounding pharmacies due to lack of human safety data.
- 2026-10-28HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of KPV acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.
Sources & FAQs
Research sources(6)
- PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD
- Orally Targeted Delivery of Tripeptide KPV via HA-Functionalized Nanoparticles
- Dissection of the anti-inflammatory effect of core and C-terminal (KPV) alpha-MSH peptides
- Alpha-MSH: An Emerging Anti-Inflammatory Antimicrobial Peptide
- Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Frequently asked questions(6)
What is KPV?
KPV is a three-amino-acid peptide (lysine-proline-valine) derived from the tail end of alpha-MSH, a natural hormone involved in immune regulation. It has potent anti-inflammatory properties at very low concentrations.
Is KPV safe?
Unknown. There are zero human clinical trials or safety studies. Animal studies report no adverse effects, but the FDA has stated it lacks human exposure data. Theoretical concerns include immunosuppression. Pregnant/breastfeeding women and those with cancer history should avoid it.
How is KPV administered?
KPV can be administered subcutaneously (injection), orally, or topically. Oral KPV may leverage the PepT1 transporter for absorption, which is upregulated in inflamed gut tissue. Advanced nanoparticle oral delivery systems are being researched.
Can I legally obtain KPV in 2026?
KPV is not FDA-approved and is absent from current Category 1 and the final 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Injectable KPV and unregulated products sold online are outside the policy.
Does KPV help with IBD or gut issues?
In animal models, KPV significantly reduces intestinal inflammation in colitis. However, there are no human trials confirming efficacy in IBD, Crohn's, or ulcerative colitis. Anecdotal reports from clinical use exist but are not published.
How does KPV differ from alpha-MSH?
KPV is just 3 amino acids from the C-terminal end of the 13-amino-acid alpha-MSH. Unlike alpha-MSH, KPV does not bind melanocortin receptors. Instead, it enters cells via the PepT1 transporter and directly inhibits NF-kB signaling. It retains anti-inflammatory activity without melanotropic effects.